The effects of slc22a1 and atm gene polymorphisms on insulin resistance in type 2 diabetic patients treated with metformin

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026423

Enrollment

Unknown

Registered

2019-10-09

Start date

2019-10-15

Completion date

Unknown

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

single arm:metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis for type 2 diabetes (WHO 1999 diagnostic criteria); 2. All patients received metformin for at least 6 months(1000-1500mg/day); 3. None of the patients were receiving insulin therapy; 4. Aged 18-80 years.

Exclusion criteria

Exclusion criteria: 1. hyperthyroidism or hypothyroidism; 2. renal failure; 3. chronic hepatic diseases; 4. malignant diseases (such as cancer); 5. autoimmune diseases; 6. pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
genotype;blood glucose;Insulin;	—

Countries

China

Contacts

Public ContactLi Yan

Shandong Provincial Qianfoshan Hospital

prof_liyan@126.com+86 13791126823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026